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Interferon-c, a known inhibitor of tumor cell growth, has been used in several protocols for the treatment of
melanoma. We have studied the molecular events underlying interferon-c-induced G0/G1 arrest in four metastatic
melanoma cell lines with different responsiveness to interferon-c. The growth arrest did not result from enhanced
expression of cyclin-dependent kinase inhibitors p21 and p27. Instead, it correlated with downregulation of cyclin E
and cyclin A and inhibition of their associated kinase activities. We show that interferon-c-induced growth
inhibition could be abrogated by overexpression of dominant negative STAT1 (signal transducer and activator of
transcription 1) in the melanoma cell line A375, suggesting that STAT1 plays a crucial part for the anti-proliferative
effect. Erythropoietin stimulation of a chimeric receptor led to a concentration-dependent STAT1 activation and
concomitant growth arrest when it contained the STAT recruitment motif Y440 of the interferon-c receptor 1. In
contrast, dose–response studies for interferon-c revealed a discrepancy between levels of STAT1 activation and
the extent of growth inhibition; whereas STAT1 was activated by low doses of interferon-c (10 U per mL), growth
inhibitory effects were only visible with 100-fold higher concentrations. Our results suggest the presence of
additional signals emanating from the interferon-c receptor, which may counteract the anti-proliferative function of
STAT1.
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Interferons (IFN), initially identified as anti-viral agents, are
implicated in a variety of biologic functions concerning anti-
proliferative effects, induction of cell differentiation, and
modulation of the immune response. They are divided into
two classes: type I IFN (comprising IFN-a and IFN-b) and
type II IFN (represented by IFN-g). Each class is character-
ized by distinct intracellular signaling mechanisms. IFN-g,
produced by activated T lymphocytes and natural killer
cells, exerts its pleiotropic effects via a receptor complex
consisting of two chains, the ligand-specific IFNGR1 and
IFNGR2, expressed on nearly all cell types (Stark et al,
1998). Binding of IFN-g leads to the oligomerization of the
receptor subunits and initiates signal transduction. Jak1
and Jak2 protein tyrosine kinases of the Janus family that
are constitutively associated with IFNGR1 and IFNGR2
receptor subunits, respectively, become activated and in
turn are thought to phosphorylate tyrosine residue 440 of
the cytoplasmic part of IFNGR1 among other cellular
substrates. The phosphotyrosine pY440 within the se-
quence Y440DKPH plays a major part in receptor activity
as it serves as a docking site for the transcription factor
STAT1 (signal transducer and activator of transcription 1).
Subsequently, STAT1 also undergoes tyrosine phosphoryla-
tion, dissociates from the receptor, forms dimers, and
translocates to the nucleus where it regulates transcription
of target genes (Darnell, 1997; Stark et al, 1998). In addition
to the ubiquitous way of IFN-g-responsive STAT1-mediated
signaling, cell-type-specific activation of two other STAT
factors was recently reported. Coactivation of STAT1 and
STAT3 after IFN-g stimulation has been described in
adipocytes (Stephens et al, 1998) and hematopoietic cells
(Sato et al, 1997). IFN-g-induced monocyte or macrophage
differentiation was shown to coincide with the activation of
STAT5 but not STAT1 (Meinke et al, 1996), which is also
mediated by Y440 of the IFNGR1 (Woldman et al, 2001).
Moreover, activation of several other signaling pathways
has been described, including the extracellular signal-
regulated kinase (Erk) pathway induced via protein tyrosine
kinase Pyk2 (Takaoka et al, 1999) or via the serine/threonine
kinase Raf-1 (David et al, 1995; Stancato et al, 1998), the
p38 mitogen-activated protein kinase (MAPK) pathway and
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the recently reported C3G/Rap1 pathway, a small G protein
signaling cascade (Alsayed et al, 2000).
Both types of IFN are known for strong anti-proliferative
and immunomodulatory effects on melanoma cells. IFN-g
was also reported to induce expression of ISGF3 compo-
nents, including STAT1, which significantly enhances
responsiveness to IFN-a/b of primed cells (Carson, 1998;
Wong et al, 1998).
As the downstream mechanisms of IFN-g-mediated
effects on growth and survival of human melanoma cells
are largely unknown we investigated the molecular events
underlying the anti-proliferative effect of IFN-g on human
melanoma cells of metastatic origin. Cell cycle analysis
revealed that the growth arrest does not result from
accumulation of cyclin-dependent kinase inhibitors. Rather,
growth inhibition was correlated with the complex down-
regulation of several proteins necessary for cell cycle
progression, primarily cyclin E, cyclin A, and the kinases
cdk4 and cdk2. In this study, we demonstrate that the
activity of IFN-g on melanoma cells is STAT1 dependent.
Most interestingly, under conditions of comparable STAT1
activation, a chimeric receptor containing the isolated
tyrosine motif Y440 is much more effective at mediating
growth inhibition than the endogenous IFN-g receptor. Our
results imply that divergent signals may emanate from the
IFN-g receptor, which could contribute to IFN-g resistance.
Results
IFN-c induces a G0/G1 arrest in human melanoma cells
involving a downregulation of cyclins and cyclin-
dependent kinases To study the anti-proliferative effect
of IFN-g on human melanoma cells, four cell lines derived
from metastatic tumor stages were chosen. After 4 d of
incubation in the presence of IFN-g, a concentration-
dependent growth inhibition was observed (Fig 1A). In three
of the tested cell lines this inhibition was evident when
concentrations of IFN-g exceeded 1000 U per mL. A375
cells exhibited the greatest inhibition in growth, whereas the
effect on WM239 and Mel-Im cells was more moderate. In
contrast, WM9 cells were relatively resistant to IFN-g,
reacting only at doses greater than 10,000 U per mL. These
findings were confirmed by cell cycle analyses. After 2 d of
treatment with IFN-g, the number of A375, WM239, and
Mel-Im cells in G0/G1 phase was increased, whereas WM9
cells remained unaffected (Fig 1B). This G0/G1 arrest in
A375 and WM239 cells was paralleled by a marginal
increase in apoptotic cells; however, the percentage of
counted sub-G1 events did not exceed 4% of total counts
(data not shown).
A known mechanism underlying the IFN-g-induced G0/G1
arrest in many cells is the upregulation of cyclin-dependent
kinase inhibitors (Yamada et al, 1995; Chin et al, 1996;
Mandal et al, 1998). None of the cell lines whose growth was
inhibited by IFN-g (A375, Mel-Im, WM239), however, showed
an upregulation of p21/Waf-1/Cip-1, p27/Kip-1, or p18/
INK4c. In fact, a decrease in the protein level of p21 and, to
a lesser extent, of p27 and p18 was observed (Fig 2). It is
also noteworthy that the basal levels of cyclin-dependent
kinase inhibitor, particularly p21, were not consistent in the
cell lines studied (Fig 2) and did not correlate with their
normal growth rate in cell culture (not shown).
Growth arrest can also be mediated by the down-
regulation of positive regulators of the cell cycle. Therefore,
we analyzed the protein expression of cyclins D1, E, and A,
and the cyclin-dependent kinases cdk4 and cdk2. Cyclin D1
expression did not significantly change after stimulation
with IFN-g in any of the melanoma cell lines (Fig 2). Protein
levels of cyclin E or cyclin A, however, were downregulated
in all melanoma cell lines after IFN-g treatment with the
exception of the IFN-g-resistant WM9 cells. We also
observed a reduction in the expression of the cyclin-
dependent kinases cdk4 and cdk2 in the IFN-g-sensitive
A375, Mel-Im, and WM239 cells but not in the IFN-g-
resistant WM9 cells.
Figure1
Effect of IFN-c on the growth of human melanoma cells. (A) A375
(circles), Mel-Im (squares), WM239 (rhombs), and WM9 cells (triangles)
were cultured for 4 d in the presence of IFN-g at different concentra-
tions. Growth was assessed by an XTT test. Values were recalculated
according to untreated controls. Error bars represent the SD of
triplicate samples. (B) For cell cycle analysis A375, Mel-Im, WM239,
and WM9 cells were incubated in medium with or without IFN-g (5000 U
per mL) for 48 h. After DNA staining with propidium iodide,
fluorescence was measured with a FACScalibur (Becton Dickinson),
and the data were further quantified using the ModFit 2.0 software
(Verity Software). Sub-G1 values were excluded from the calculation.
Error bars represent the SD of three independent experiments.
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These findings suggest that IFN-g inhibits growth of
melanoma cells by a mechanism that does not involve
cyclin-dependent kinase inhibitor upregulation, but rather
entails a complex downregulation of G1/S cyclins and
cyclin-dependent kinases.
Defects in STAT1 expression do not explain differences
in IFN-c responsiveness We next examined STAT1 ex-
pression in the melanoma cell lines, because reduced
responsiveness to IFN may result from a lack of STAT1
expression (Wong et al, 1997). The basal protein levels of
STAT1 in untreated cells were comparable and did not
correlate with their responsiveness to IFN-g (Fig 3A).
Moreover, all the cell lines, including WM9 cells, exhibited
strong upregulation of STAT1 protein expression within 24 h
after stimulation, whereas Erk levels remained unchanged.
In all the cell lines tested, including WM9 cells, IFN-g
induced strong phosphorylation of STAT1 after 15 min of
stimulation. STAT1 phosphorylation was still pronounced in
A375 and Mel-Im cells after 24 h of stimulation, whereas it
was considerably reduced in WM239 and WM9 cells (Fig
3A). STAT1 phosphorylation was paralleled by the appear-
ance of corresponding DNA-binding activities in EMSA
analysis using the SIE-oligo (Fig 3B). This probe binds both
STAT1 and STAT3. The presence of anti-STAT1 antibodies
but not of anti-STAT3 antibodies significantly reduced the
binding activity in nuclear extracts of IFN-g-treated A375-
cells (Fig 3C). Moreover, the mobility of the IFN-g-induced
DNA-binding activity was clearly different from the STAT3
signals observed upon OSM stimulation (Fig 3C).
STAT1 activation is crucial for IFN-c-induced growth
inhibition of A375 cells To study the role of STAT1 in IFN-g
induced growth inhibition we employed tripartite chimeric
receptor constructs (Gerhartz et al, 1996; Strobl et al, 2001).
These constructs contain the extracellular region of the
mouse erythropoietin receptor (EPOR) fused to the trans-
membrane and truncated membrane-proximal box1/box2
region (i.e., the Jak binding region) of the interleukin-6 signal
transducer gp130, without or with the seven amino acid
Figure 2
IFN-c leads to complex downregulation of G1/S cyclins and cyclin-
dependent kinases. A375, Mel-Im, WM239, and WM9 cells were
stimulated with IFN-g (5000 U per mL) for 48 h. Equal amounts of total
cell lysates (30 mg protein) were separated on a 15% SDS
polyacrylamide gel followed by western blot analysis with antibodies
to the indicated proteins.
Figure3
Activation of STAT1 signaling in IFN-c-treated melanoma cells. (A)
Phosphorylation and expression of STAT1 in A375, Mel-Im, WM239,
and WM9 cells stimulated with IFN-g (5000 U per mL) for 15 min and 24
h. Equal amounts of total cell lysates (30 mg protein) were separated on
a 7.5% SDS polyacrylamide gel followed by western blot analysis using
antibodies against phospho-STAT1, STAT1, and Erk1/2. (B) A375, Mel-
Im, WM239, and WM9 cells were stimulated with IFN-g (5000 U per mL)
for the indicated times. Nuclear extracts containing 5 mg of protein were
used for an EMSA with the SIEm67 probe. The position of homodimers
of STAT1 is indicated. (C) IFN-g does not activate STAT3. Nuclear
extracts were prepared from A375 cells stimulated with IFN-g (500 U
per mL) or with OSM (10 ng per mL) for 15 min. Equal amounts of
nuclear extracts (2.5 mg) was used for an EMSA with the SIEm67 probe,
if indicated after preincubation (15 min at room temperature) with 3 mg
anti-STAT1 or anti-STAT3 antibodies.
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STAT1 recruitment motif (Y440) from the IFNGR1 (EGDB and
EGDBY440, respectively, Fig 4A,B, left upper panels). Thus,
as the endogenous IFN-g receptor, EGDBY440 has the
ability to activate STAT1. Except for the STAT recruitment
motif, however, both receptors are different in sequence.
Stably transfected A375 clones with similar levels of
surface receptor expression were isolated (Fig 4A,B, left
lower panels). As previously reported (Kortylewski et al,
1999), clones expressing EGDB did not exhibit STAT
activation after stimulation with EPO (Fig 4A, right upper
panel) and proliferated unrestrained (Fig 4A, right lower
panel). In contrast, clones expressing EGDBY440 (Fig 4B,
left panels) demonstrated a strong EPO-induced STAT1
activation (Fig 4B, right upper panel). In addition, growth of
these clones was efficiently growth inhibited by EPO (Fig
4B, right lower panel) as a result of a G0/G1 arrest (data not
shown).
Like IFN-g, EPO decreased the expression of cyclin E,
cyclin A and, to a lesser extent, of cdk4 and cdk2 within 24
h of treatment in EGDBY440 cells (Fig 5). Whereas p21 and
p18 protein levels remained relatively stable, levels of p27
decreased. The downregulation of cyclin E and cyclin A,
together with their kinase partner cdk2, was also evident by
reduced levels of kinase activity of the respective cyclin/cdk
complexes (data not shown). We conclude that the
presence of the STAT1 recruitment module Y440 within
the chimeric receptor was sufficient to mediate an IFN-g-
like growth arrest of A375 cells.
In a separate attempt to elucidate the role of STAT1 in
IFN-g-induced growth inhibition, we examined stable A375
transfectants expressing STAT1F, a dominant negative form
of STAT1 in which the tyrosine residue Y701, necessary for
STAT1 phosphorylation and dimerization, is replaced by
phenylalanine (Nakajima et al, 1996; Kortylewski et al,
1999). As presented in Fig 6, A375 cells overexpressing
STAT1F were almost completely resistant to IFN-g when
compared with mock transfectants, suggesting that STAT1
is a crucial mediator for the growth arrest elicited by IFN-g.
Figure 4
STAT1 activation is sufficient to confer a growth inhibitory effect
on A375 cells. Comparison of two hybrid receptors: EGDB (A) and
EGDBY440 (B). Upper left panels: schematic representation of receptor
chimeras expressed in A375 cells. Lower left panels: receptor
expression on the surface of A375 transfectants. Cells were incubated
with a polyclonal rabbit-anti-mouse EPOR anti-serum followed by
staining with phycoerythrin-conjugated donkey-anti-rabbit IgG anti-
serum and measured by cytofluorometry. Each panel contains the
histograms of the indicated transfectants (black) in comparison with
those of transfectants incubated with secondary antibody alone (dotted
line) and of parental A375 cells (solid line) to show unspecific binding of
the polyclonal anti-sera. Upper right panels: STAT1 activation in cells
stimulated with EPO (10 U per mL) for the times indicated. Nuclear
extracts containing 5 mg of protein were used for an EMSA with the
SIEm67 probe. The position of STAT1 homodimers is indicated. Lower
right panels: Effect of EPO on the growth of transfectants. Cells were
cultured for 4 d in the presence of EPO at different concentrations.
Growth was assessed by an XTT test, values were recalculated
according to untreated controls. Error bars represent the SD of
triplicate samples.
Figure5
Similar effects on the expression of cell cycle regulatory molecules
mediated by the IFN-c receptor and the chimeric receptor
EGDBY440. A375 cells stably expressing the EGDBY440 receptor
were stimulated with IFN-g (5000 U per mL) or EPO (10 U per mL) for
the indicated times. Equal amounts of total cell lysates (30 mg protein)
were separated on a 15% SDS polyacrylamide gel followed by western
blot analysis.
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A discrepancy in the level of activated STAT1 and the
extent of IFN-c-induced growth inhibitory effects While
examining the responsiveness of the stable transfectants
expressing EGDBY440 in more detail, we observed a
striking difference between the signal transduction of
IFN-g (via the endogenous receptor) and EPO (via the
transfected receptor): stimulation of EGDBY440 transfec-
tants with increasing doses of EPO induced DNA-binding
activity of STAT1, even at concentrations as low as 0.1 U per
mL (Fig 7A, right panels). This increase in STAT1 DNA
binding activity was paralleled by a proportionally enhanced
inhibition in the growth of transfectants (Fig 7A, lower panel
on the right). Similar to the parental A375 cells (Fig 1), IFN-g-
induced growth inhibition of EGDBY440 transfectants was
detectable at concentrations as low as 1000 U per mL. Gel
shift assays indicated that, although the activation of STAT1
by IFN-g was evident at doses as low as 10 U per mL and
was near maximal at 100 U per mL, this dose was too low to
affect cell growth (Fig 7A, left panels). The induction of
STAT1 protein expression by both EPO and IFN-g paralleled
the respective dose–response of STAT1 activity to these
factors (Fig 7B).
To study further this apparent discrepancy between IFN-
g-induced STAT1 activity and growth inhibition, we exam-
ined in detail the kinetics of STAT1 activation with respect to
its tyrosine and serine phosphorylation and DNA binding.
Doses of IFN-g and EPO known to induce similar STAT1
activity but affecting cell growth with minimal (1000 U per
mL IFN-g) or maximal (10 U per mL EPO) efficiency were
compared.
The short-term kinetics of STAT1 tyrosine and serine
phosphorylation were comparable for both stimuli (Fig 7C).
Two longer-term assays also showed no differences
between IFN-g and EPO stimulation: addition of IFN-g and
EPO resulted in comparable levels of GAS-element-
mediated reporter gene activity after 18 h; stimulation of
gene activity was not additive, as the addition of both IFN-g
and EPO did not further increase gene activity (Fig 7D).
Moreover, both agents induced similar STAT1 DNA-binding
activities at time points from 14 to 48 h (Fig 7E). Therefore,
factors other than STAT1 are likely to account for the
differential response of EGDBY440 cells to the two
cytokines.
No difference could be observed for STAT5 and IRF-1 as
monitored by EMSA using probes for the respective
transcription factors (Fig 7E). The time course of STAT5
activation paralleled the observed STAT1 activation,
whereas DNA binding of IRF-1 was prominent 14 h after
stimulation and slowly declined afterwards. C/EBPb and c-
myc, two other transcription factors known to be induced
by IFN-g in several cell types, were slightly downregulated
by both stimuli after 24 h (Fig 7F), whereas STAT1 was
dramatically upregulated.
Discussion
The growth inhibitory effect of IFN-g on melanoma cells has
long been known (Brown et al, 1987; Garbe and Krasagakis,
1993). IFN-g has been used in adjuvant cytokine therapy
studies (Agarwala and Kirkwood, 1996) and in gene
therapeutic approaches in mouse models (Yu and Tho-
mas-Tikhonenko, 2001) as well as in clinical trials (Nemu-
naitis et al, 1999). The mechanism of IFN-g-induced growth
arrest of melanoma cells, however, has not been examined
in greater detail.
IFN-c-induced growth arrest correlates with a complex
downregulation of G1/S cyclins and cyclin-dependent
kinases This study indicated that IFN-g leads to G0/G1
growth arrest in A375, WM239, and Mel-Im cells, whereas
WM9 cells are resistant to IFN-g. This growth arrest
correlated with lower levels of certain cyclins (cyclin A and
cyclin E) and cyclin-dependent kinases (cdk2 and cdk4).
Levels of cyclin-dependent kinase inhibitors, however, were
not affected or even drastically decreased (e.g., p21 in Mel-
Im and WM239 cells, Fig 2). This finding was somewhat
unexpected as IFN-g induces p21 in a number of cell types,
including multiple myeloma (Urashima et al, 1997), glio-
blastoma (Kominsky et al, 1998), colon adenocarcinoma
(Hobeika et al, 1999), and breast cancer cells (Gooch et al,
2000), as well as in normal bone marrow macrophages
(Xaus et al, 1999). Upregulation could be attributed to direct
STAT1-mediated activation of the p21 gene promoter (Chin
et al, 1996). An upregulation of p27 by IFN-g was observed
together with an increase in protein levels of other inhibitors,
such as p21 (Mandal et al, 1998), p18/INK4c (Yamada et al,
1995), or with a concomitant rapid downregulation of
positive cell cycle regulators, such as cyclin A, cdk2,
cdc2, and c-myc (Harvat and Jetten, 1996; Harvat et al,
1997). It should be noted that p27 and p21 inhibitors are
upregulated after treatment with interleukin-6 or upon g-
irradiation at least in A375 and WM239 cells (Kortylewski et
al, 1999), and data not shown). IFN-g-mediated cell cycle
arrest without concomitant upregulation of p21 and p27,
however, is not without precedent: in human mesothelioma
cells IFN-g appears to be able to induce a G0/G1 block
Figure 6
Dominant negative STAT1F abrogates IFN-c-mediated growth
inhibition. A375 cells transfected with the pCAGGS control vector
(open squares) or with an expression construct for STAT1F (closed
squares) were incubated for 4 d with IFN-g at different concentrations.
Cell growth was assessed by an XTT test, and values were recalculated
according to untreated controls. Error bars represent the SD of
triplicate samples.
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independent of p21 and p27 inhibitors, with a concurrent
reduction of cyclin A expression and its associated kinase
activity (Vivo et al, 2001).
STAT1 deﬁciency does not account for IFN-c resistance
of WM9 cells Cytokine resistance of melanoma cells is
often correlated with diminished Jak/STAT signaling (Wong
et al, 1997, 1998; Pansky et al, 2000; Bo¨hm et al, 2001).
Wong et al, 1997 proposed that a deficiency in ISGF3
components may be responsible for the resistance of
melanoma cells to IFN. Indeed, reduced levels of STAT1
were found in certain IFN-resistant cells (Wong et al, 1997;
Pansky et al, 2000), and the restoration of normal STAT1
levels by IFN-g induction or by overexpression or STAT1 or
IRF-1 is sufficient to augment the responsiveness to IFN
(Wong et al, 1997, 1998, 2002). As shown in this study,
however, differences in the sensitivity of melanoma cells to
IFN-g cannot be explained entirely by differential STAT1
expression, as all cells expressed functional STAT1 and
STAT1 protein levels substantially increased during IFN-g
treatment. Similarly, no correlation between the resistance
of melanoma cells to IFN-a2 and IFN-b and STAT1
expression or activation was found in a recent study
(Chawla-Sarkar et al, 2002).
Figure 7
A discrepancy in the level of activated STAT1 and the extent of IFN-c-induced growth inhibitory effects. (A) Upper panel: EGDBY440
transfectants were stimulated for 15 min. Nuclear extracts containing 5 mg of protein were used for an EMSA with the SIEm67 probe. The position of
homodimers of STAT1 is shown. Lower panel: effects of IFN-g and EPO on growth of transfectants. Cells were cultured for 4 d in the presence of
EPO at different concentrations. Growth was assessed by an XTT test. Means of triplicate values were recalculated according to untreated controls
and extrapolated for the shown concentrations. (B) Cells were stimulated for 24 h with doses of IFN-g or EPO as indicated. Equal amounts of total
cell lysates (30 mg protein) were separated on a 7.5% SDS polyacrylamide gel followed by western blot analysis with antibodies against STAT1 and
STAT3. (C) Cells were stimulated for the indicated times with IFN-g (1000 U per mL) and EPO (10 U per mL). Equal amounts of total cell lysates (30 mg
protein) were separated on a 6% SDS polyacrylamide gel followed by western blot analysis with antibodies directed against phosphotyrosine-
STAT1, phosphoserine-STAT1, and STAT1. (D) Activation of a pIRF-1(GAS)-luc transcriptional reporter plasmid in A375 transfectants treated with
IFN-g (1000 U per mL) or EPO (10 U per mL) for 18 h. (E) EGDBY440 transfectants were stimulated with IFN-g (1000 U per mL) or EPO (3.5 U per mL)
for the indicated periods of time. EMSA analysis of the DNA binding activity of STAT1, STAT5, and IRF-1. (F) EGDBY440 transfectants were
stimulated with IFN-g (1000 U per mL) or EPO (3.5 U per mL) for the indicated periods of time. Equal amounts of nuclear extracts (30 mg protein) were
separated on a 6% SDS polyacrylamide gel followed by western blot analysis using antibodies directed against STAT1, C/EBP and c-myc and Erk2.
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Crucial role for STAT1 in IFN-c-mediated growth inhibi-
tion of A375 cells The importance of STAT1 in IFN-g-
mediated growth inhibition of A375 cells was demonstrated
by two different approaches: (1) a chimeric receptor was
able to mediate growth inhibition of A375 transfectants after
addition of the STAT activating tyrosine module Y440 from
the IFNGR1, and (2) overexpression of a dominant negative
form of STAT1 in A375 cells resulted in abrogation of the
growth inhibitory effect of IFN-g. We conclude that STAT1 is
an essential mediator of IFN-g-dependent G0/G1 growth
arrest as has been reported for other tumor types (Brom-
berg et al, 1996; Urashima et al, 1997; Kominsky et al, 1998;
Hobeika et al, 1999; Xaus et al, 1999; Gooch et al, 2000).
Evidence for divergent signals emanating from the IFN-c
receptor Interestingly, STAT1 activation by the chimeric
receptor in EGDBY440 transfectants induced a much more
pronounced growth inhibition when compared with activa-
tion via the endogenous IFN-g-R. EGDBY440 contains
the same STAT recruitment motif as the IFN-g receptor. In
the chimera, however, Jak activation is mediated by the
membrane-proximal region of gp130, the signal transducing
chain of interleukin-6-type cytokines. It could be possible
that the gp130 part of the receptor might convey growth
inhibiting signals, in addition to those mediated by STAT1.
This explanation is unlikely, however, as the shorter chimeric
receptor EGDB (which lacks the STAT1 recruitment module)
was not able to activate STAT nor did it affect the growth of
A375 cells (Kortylewski et al, 1999) (Fig 4A). This observa-
tion is supported by the finding that EGDB (in contrast to
EGDBY440) lacks the ability to upregulate the expression of
typical IFN-inducible mRNA in fibrosarcoma cells (Strobl
et al, 2001). The kinetics of STAT1 activation after stimulation
of EGDBY440 transfectants with EPO or IFN-g were similar,
precluding a differential sensitivity of the two receptor
complexes, e.g., against feedback inhibitors. Therefore, we
hypothesize that the activity of STAT1 as a mediator of
growth inhibition may be counteracted by growth promoting
signals elicited by the IFN-g receptor.
Our observations are consistent with recent reports
providing evidence for the existence of STAT1-independent
pathways elicited by the IFN-g receptor (Ramana et al,
2000, 2001; Gil et al, 2001). Stimulation of an IFN-g receptor
with a phenylalanine mutation of Y440 substantially
enhanced serum-induced proliferation of mouse fibroblast
cells, whereas the wild-type receptor inhibited this effect
(Ramana et al, 2001). Moreover, IFN-g induced survival and/
or proliferation of bone marrow cells only in the absence of
STAT1 (Gil et al, 2001). A series of genes is induced by IFN-g
in cells derived from STAT1–/– mice (Ramana et al, 2001).
Simultaneous activation of two apparently contradictory
signals from a single receptor is not without precedent. The
interleukin-6 signal transducer gp130 can simultaneously
induce growth-enhancing and growth-suppressing signals
in myeloid M1 and Ba/F03 pro-B cells (Nakajima et al, 1996;
Fukada et al, 1998). The tumor necrosis factor receptor 1
also elicits both pro-apoptotic signals and anti-apoptotic
signals (Hsu et al, 1996).
In therapeutic approaches involving IFN-g as growth
inhibitor it would be desirable to trigger growth arrest
without concomitant activation of growth promoting signals.
Therefore, future studies should focus on the further
analysis of divergent IFN-g-induced pathways and on
possible mechanisms for their selective modulation.
Materials and Methods
Cell culture and reagents Human A375 melanoma cells were
purchased from the American Type Culture Collection (CRL-1619).
WM239 and WM9 cells (Herlyn, 1990) were received from Dr R.S.
Kerbel (Sunnybrook Health Science Center, Toronto, Canada). Mel-
Im cells are described in Jacob et al (1995). Cells were grown in
RPMI 1640 medium (Gibco Life Technologies, Karlsruhe, Germany)
supplemented with 5% fetal bovine serum, 50 mg penicillin per mL,
and 100 mg streptomycin per mL. Human recombinant IFN-g was
purchased from PeproTech (Pepro Tech, London, UK). Human
recombinant erythropoietin was kindly provided by Drs J. Burg and
K.-H. Sellinger (Roche, Penzberg, Germany). Oncostatin M was
purchased from PeproTech. All experiments were conducted with
the approval of the RWTH Aachen Medical School.
Generation of transfectants The chimeric receptors EGDB and
EGDBY440, combining the extracellular portion of the murine EPO
receptor and the cytoplasmic portion of gp130, were constructed
as described before (Gerhartz et al, 1996). Receptor EGDB retains
only the membrane proximal box 1/2 region, whereas receptor
EGDBY440 also contains the seven amino acid (Y440) STAT1
recruitment motif from IFNGR1. The wild-type and dominant
negative STAT1 constructs in pCAGGS plasmids were gifts from
Koichi Nakajima and Toshio Hirano (Osaka, Japan). Stable
transfections were performed as described previously. In short,
2  106 cells suspended in 0.8 mL medium with 30 mg of the
respective plasmid DNA were subjected to a double pulse (3.0 kV/
99 ms) using an Electro Square Porator T820 from BTX (San Diego,
California). Transfectants were later grown in the presence of 1.2
mg per mL of G418 (Gibco BRL) and clones expressing exogenous
protein were selected by flow cytometry. For monitoring the
expression of chimeric receptors EGDB and EGDBY440, approxi-
mately 106 cells were stained with polyclonal rabbit anti-serum
against the extracellular region of the murine EPO receptor (kindly
provided by Dr U. Klingmu¨ller, Freiburg, Germany). As a secondary
antibody, a phycoerythrin-conjugated donkey anti-rabbit IgG anti-
body (Dianova, Hamburg, Germany) was used. Fluorescence data
were collected with a FACSCalibur and further analyzed using the
CellQuest software (Becton Dickinson, Heidelburg, Germany).
Heterologous expression of STAT1 and STAT1F was assessed
with a monoclonal antibody directed against the hemagglutinin tag
from BAbCO (BabCo, Richmond, CA) as described before
(Kortylewski et al, 1999). At least two single clones from each
transfection were chosen for further experiments and gave similar
results.
Growth inhibition assay Viable cells (3  103) were seeded in
triplicate into 96-microwell plates and incubated with various
concentrations of cytokines in medium containing 1% fetal bovine
serum. After 4 d of culture an XTT colorimetric assay (Roche) was
performed as described previously (Kortylewski et al, 1999). The
percentage of growth inhibition was calculated in relation to the
growth of untreated control cells.
DNA staining and ﬂow cytometry For the analysis of DNA
content 5  105 cells were stained with propidium iodide using the
CycleTEST Plus DNA Reagent Kit (Becton Dickinson) according to
the manufacturer’s protocol. Fluorescence data were collected
with a FACSCalibur (Becton Dickinson) and further analyzed using
the ModFit 2.0 software (Verity Software, Topsham, ME).
Electrophoretic mobility shift assays (EMSA) Nuclear extracts
were prepared according to Wegenka et al (1993) and protein
concentrations were measured using the Bio-Rad protein assay
(Bio-Rad, Mu¨nchen, Germany) Briefly, 10 fmol (10,000 cpm) of an
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a-32P-labeled double-stranded oligonucleotide was added to
nuclear extracts containing 5 mg of protein and incubated in gel
shift incubation buffer: 10 mM HEPES pH 7.8, 1 mM EDTA, 5 mM
MgCl2, 10% glycerol, 5 mM dithiothreitol, 0.7 mM phenylmethylsul-
fonyl fluoride, 0.1 mg poly(dI-dC) per mL, and 1 mg bovine serum
albumin per mL for 10 min at room temperature. The protein-DNA
complexes were separated on a 4.5% polyacrylamide gel contain-
ing 7.5% glycerol in 0.25-fold TBE at 20 V per cm for 4 h. Gels were
fixed in a water solution of 10% methanol and 10% acetic acid for
30 min, dried, and autoradiographed. Data were further analyzed
using a Personal FX Phosphorimager with the Quantity One
software (Bio-Rad). The oligo probes correspond to the c-fos
promoter (m67SIE: 50-GAT CCG GGA GGG ATT TAC GGG AAA
TGC TG-30, binds STAT1 and STAT3) or to the b-casein promoter
(50-TTA GAT TTC TAG GAA TTC AAT C-30, binds STAT5). The
sequence for the IRF-1 binding probe is 50-GAT CCT CGG GAA
AGG GAA ACC GAA ACT GAA GCC-30. For supershift analysis,
nuclear extracts were incubated for 15 min at room temperature in
the presence of polyclonal anti-STAT1 (E23) and anti-STAT3 (C20)
antibodies (Santa Cruz Biotechnology, Heidelburg, Germany)
before the radioactive probe was added.
Immunoblotting analysis Cells were lyzed on the plate in lysis
buffer containing 1% Triton X-100, 1% sodium deoxycholate, 0.1%
sodium dodecyl sulfate (SDS), 20 mM Tris, pH 7.2, 158 mM NaCl, 5
mM EDTA, 50 mM NaF, 1 mM Na2VO3, 1 mM phenylmethylsulfonyl
fluoride, 5 mg aprotinin per mL, and 5 mg leupeptin per mL. Lysates
were further cleared by centrifugation at 12,000  g and the protein
concentrations were determined with the protein assay reagent
from Bio-Rad. Equal amounts of protein were separated by SDS/
polyacrylamide gel electrophoresis, transferred to PVDF membrane
(GelmanSciences, Ann Arbor, MI), probed with the respective
antibodies and detected for signals using the ECL system
(Amersham Pharmacia, Freiburg, Germany). The antibodies used
were monoclonal anti-p21 (SX118; Pharmingen, Heidelburg, Ger-
many), polyclonal phospho-specific anti-STAT1 antibodies (tyrosine
701 and serine 727; New England Biolabs, Frankfort a.M.,
Germany) and polyclonal anti-STAT1 (E-23), anti-cdk2 (M2), anti-
cdk4 (H-303), anti-cyclin D1 (R-124), anti-cyclin E (C-19), anti-cyclin
A (C-19), anti-p18 (N-20), anti-p27 (C-19), anti-Rb (C-15), anti-Erk1
(C-16), and anti-Erk2 (C-14) antibodies (Santa Cruz Biotechnology).
Histone H1 kinase assay Histone H1 kinase assays were
performed according to Hermeking et al (1995). Briefly, the anti-
cyclin E (C-19) or anti-cyclin A (C-19) immunoprecipitates were
prepared from 150 mg of lysate protein and were incubated for 20
min at 301C in 20 mL of kinase buffer (20 mM MgCl2, 10 mM EGTA,
40 mM HEPES pH 7.0) with 1 mg of histone H1 (Roche) and 1 mL of
300 Ci per mmol of [g32P]-adenosine triphosphate (Amersham).
After stopping the reaction with 2  SDS sample buffer, phos-
phorylated proteins were resolved by 12% SDS/polyacrylamide gel
electrophoresis and signals were analyzed using a Personal FX
Phosphorimager with the Quantity One software (Bio-Rad).
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